ストックスクリーナーアプリを入手
16.87
0.84%
0.14
アフターアワーズ：
16.81
-0.06
-0.36%
前日終値:
$16.73
開ける：
$16.51
24時間の取引高:
4.75M
Relative Volume:
3.22
時価総額：
$2.81B
収益：
$890.53M
当期純損益:
$30.57M
株価収益率:
-18.34
EPS:
-0.92
ネットキャッシュフロー:
$80.53M
1週間 パフォーマンス:
-2.26%
1か月 パフォーマンス:
+3.69%
6か月 パフォーマンス:
+14.37%
1年 パフォーマンス:
-41.93%
1日の値動き範囲:
$16.49
$17.21
1週間の範囲:
$16.27
$17.86
52週間の値動き範囲:
$14.15
$32.59
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
名前
Acadia Pharmaceuticals Inc
セクター
電話
858-558-2871
住所
12830 EL CAMINO REAL, SAN DIEGO
ACAD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
16.87 | 2.81B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-03-12 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-12 | 繰り返されました | Needham | Buy |
| 2024-01-30 | 開始されました | Robert W. Baird | Outperform |
| 2024-01-24 | アップグレード | Needham | Hold → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-06 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-17 | 開始されました | UBS | Buy |
| 2023-10-10 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-11-04 | ダウングレード | Goldman | Neutral → Sell |
| 2022-11-01 | 開始されました | Loop Capital | Hold |
| 2022-08-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-21 | ダウングレード | Jefferies | Buy → Underperform |
| 2022-06-16 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-16 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2021-12-21 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-06-10 | 開始されました | Berenberg | Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | ダウングレード | Goldman | Buy → Neutral |
| 2021-04-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-04-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-05 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-03-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2020-12-16 | 開始されました | Mizuho | Buy |
| 2020-11-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-07 | アップグレード | Stifel | Hold → Buy |
| 2020-04-16 | 開始されました | Jefferies | Buy |
| 2020-03-31 | アップグレード | Goldman | Neutral → Buy |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | 開始されました | Oppenheimer | Perform |
| 2019-10-01 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-09-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 繰り返されました | Needham | Buy |
| 2018-12-10 | 開始されました | Canaccord Genuity | Hold |
| 2018-09-21 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-08-06 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
Acadia Pharmaceuticals to Present at J.P. Morgan Healthcare Conference: Pioneering CNS Treatment Innovations - StockTitan
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 2.9%What's Next? - MarketBeat
Schizophrenia Market Predicted to See Upsurge Through 2034, - openPR
State Street Corp Acquires 173,084 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals Awards Stock Options, RSUs to New Hires in Neuroscience Expansion - StockTitan
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Position Reduced by Fmr LLC - MarketBeat
ACADIA Pharmaceuticals' SWOT analysis: stock outlook amid Daybue challenges - Investing.com
Acadia closes on $150M FDA voucher sale - MSN
Y Intercept Hong Kong Ltd Sells 39,245 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Neo Ivy Capital Management Reduces Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals Secures $150M Windfall from Priority Review Voucher Sale, Boosts R&D Pipeline - StockTitan
Pharma Pulse 12/10/24: Did Industry Fumble the DSCSA Deadline? Operationalizing Bispecifics Resources & more - Pharmaceutical Executive
Postoperative Pain Market: Market Outlook, Epidemiology Insights, Therapies, Key Companies in the Market | ACADIA Pharmaceuticals, Adynxx, Apsen Farmaceutica, Arthritis Innovation Corporation, Cali - Barchart
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer - BioSpace
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead - FiercePharma
Acadia Buys Saniona Tremor Drug - San Diego Business Journal
Walleye Capital LLC Has $628,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat
Pharma Pulse 12/5/24: Gaps in Publicly Funded Non-Inferiority Clinical Trials, Are GLP-1s Eliminating the Need for Bariatric Surgery? & more - Pharmaceutical Executive
The Manufacturers Life Insurance Company Sells 48,809 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Jacobs Levy Equity Management Inc. Sells 143,688 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
BNP Paribas Financial Markets Boosts Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options - MSN
Ryan Reynolds' Latest Film: 'More To Parkinson's' 08/19/2024 - MediaPost Communications
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Erste Asset Management GmbH Makes New $3.80 Million Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Significant Growth in Short Interest - MarketBeat
The week in deals: Acadia taps Saniona for GABRA3 modulator, and more - BioCentury
Rockefeller Capital Management L.P. Has $17.53 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Edgestream Partners L.P. Raises Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
37,683 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Intech Investment Management LLC - MarketBeat
Zacks Research Has Strong Estimate for ACAD FY2024 Earnings - MarketBeat
Acadia signs licensing deal for essential tremor drug candidate - MSN
Fred Alger Management LLC Raises Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Fisher Asset Management LLC Acquires 31,980 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE launch faces hurdles - Investing.com India
Acadia signs deal with Saniona for SAN711 rights - The Pharma Letter
Saniona’s CEO: “The deal with Acadia is significant”BioStock - BioStock - Connecting Innovation and Capital
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET (NASDAQ:ACAD) - Seeking Alpha
Saniona Cash Worries Ease With Acadia Neuro Biobucks Pact - Citeline
ACAD Signs License Deal With Saniona for Rights to Neurology Drug - Yahoo Finance
Acadia licenses Saniona’s SAN711 for essential tremor in deal worth up to $610m - World Pharmaceutical Frontiers
Acadia snaps up an essential tremor drug after field’s summer setbacks - Endpoints News
Acadia signs agreement with Saniona to commercialise SAN711 - Pharmaceutical Technology
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 - BioSpace
Acadia secures Saniona's experimental tremor drug in $600M deal - FirstWord Pharma
Saniona signs license agreement with Acadia Pharmaceuticals for SAN711 - Marketscreener.com
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for San711 - Marketscreener.com
Acadia licenses novel treatment for essential tremor By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711 - MarketWatch
Acadia nabs rights to Saniona's tremor asset in $582M biobucks deal - Fierce Biotech
Acadia Pharmaceuticals Inc (ACAD) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):